{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:13:34Z","timestamp":1794539614186,"version":"4.9.1"},"reference-count":120,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.eururo.2022.01.040","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T08:10:46Z","timestamp":1645517446000},"page":"476-488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"title":["Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review"],"prefix":"10.1016","volume":"81","author":[{"given":"Eduard","family":"Roussel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Capitanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kutikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert","family":"Oosterwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Gorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.01.040_b0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","article-title":"International variations and trends in renal cell carcinoma incidence and mortality","volume":"67","author":"Znaor","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0015","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/MLR.0000000000000657","article-title":"Understanding treatment disconnect and mortality trends in renal cell carcinoma using tumor registry data","volume":"55","author":"Smaldone","year":"2017","journal-title":"Med Care"},{"key":"10.1016\/j.eururo.2022.01.040_b0020","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2214\/AJR.14.12502","article-title":"Solid renal masses: what the numbers tell us","volume":"202","author":"Kang","year":"2014","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0025","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ejrad.2014.02.026","article-title":"Utility and limitations of 3-Tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors","volume":"83","author":"Sevcenco","year":"2014","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.juro.2014.07.102","article-title":"Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate","volume":"193","author":"Johnson","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamasurg.2018.4602","article-title":"Association of prevalence of benign pathologic findings after partial nephrectomy with preoperative imaging patterns in the United States from 2007 to 2014","volume":"154","author":"Kim","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.eururo.2022.01.040_b0040","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2015.07.072","article-title":"Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy","volume":"69","author":"Marconi","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0045","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.juro.2015.11.029","article-title":"Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature","volume":"195","author":"Patel","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.juro.2014.06.067","article-title":"Grade heterogeneity in small renal masses: potential implications for renal mass biopsy","volume":"193","author":"Ball","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0055","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.01.040_b0060","doi-asserted-by":"crossref","first-page":"W557","DOI":"10.2214\/AJR.14.13375","article-title":"Renal masses with equivocal enhancement at CT: characterization with contrast-enhanced ultrasound","volume":"204","author":"Bertolotto","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0065","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2214\/ajr.178.6.1781499","article-title":"Differentiation of subtypes of renal cell carcinoma on helical CT scans","volume":"178","author":"Kim","year":"2002","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0070","doi-asserted-by":"crossref","first-page":"W421","DOI":"10.2214\/AJR.10.4718","article-title":"MRI features of renal oncocytoma and chromophobe renal cell carcinoma","volume":"195","author":"Rosenkrantz","year":"2010","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2214\/AJR.12.9451","article-title":"Differentiation of papillary renal cell carcinoma subtypes on CT and MRI","volume":"201","author":"Egbert","year":"2013","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0080","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2214\/AJR.12.10204","article-title":"Are there useful CT features to differentiate renal cell carcinoma from lipid-poor renal angiomyolipoma?","volume":"201","author":"Yang","year":"2013","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0085","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00261-020-02644-x","article-title":"Lexicon for renal mass terms at CT and MRI: a consensus of the Society of Abdominal Radiology Disease-focused Panel on Renal Cell Carcinoma","volume":"46","author":"Shinagare","year":"2021","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0090","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.juro.2015.01.026","article-title":"Re: Characterizing solid renal neoplasms with MRI in adults","volume":"193","author":"Siegel","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0095","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1148\/radiol.12111205","article-title":"Small (<4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging","volume":"263","author":"Sasiwimonphan","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2022.01.040_b0100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1148\/radiol.2020192070","article-title":"Diagnostic performance of MRI in the detection of renal lipid-poor angiomyolipomas: a systematic review and meta-analysis","volume":"296","author":"Wilson","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2022.01.040_b0105","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1148\/radiol.2018171557","article-title":"Diagnostic performance and interreader agreement of a standardized MR imaging approach in the prediction of small renal mass histology","volume":"287","author":"Kay","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2022.01.040_b0110","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.juro.2017.04.089","article-title":"Diagnostic accuracy of multiparametric magnetic resonance imaging to identify clear cell renal cell carcinoma in cT1a renal masses","volume":"198","author":"Canvasser","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0115","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00330-020-07093-0","article-title":"Prospective performance of clear cell likelihood scores (ccLS) in renal masses evaluated with multiparametric magnetic resonance imaging","volume":"31","author":"Steinberg","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2214\/AJR.14.13930","article-title":"DWI for renal mass characterization: systematic review and meta-analysis of diagnostic test performance","volume":"205","author":"Kang","year":"2015","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00330-014-3380-x","article-title":"Multiparametric magnetic resonance imaging for the differentiation of low and high grade clear cell renal carcinoma","volume":"25","author":"Cornelis","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0130","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1148\/radiol.12112260","article-title":"Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings","volume":"265","author":"Lanzman","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2022.01.040_b0135","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13550-017-0329-5","article-title":"Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression","volume":"7","author":"Rowe","year":"2017","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.eururo.2022.01.040_b0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0090-4295(96)00095-7","article-title":"Renal oncocytoma: preoperative diagnosis using technetium 99m sestamibi imaging","volume":"48","author":"Gormley","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2022.01.040_b0145","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.celrep.2015.10.059","article-title":"The genomic landscape of renal oncocytoma identifies a metabolic barrier to tumorigenesis","volume":"13","author":"Joshi","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.eururo.2022.01.040_b0150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/RLU.0000000000000670","article-title":"Initial experience using 99mTc-MIBI SPECT\/CT for the differentiation of oncocytoma from renal cell carcinoma","volume":"40","author":"Rowe","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2022.01.040_b0155","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eururo.2015.08.056","article-title":"Prospective evaluation of 99mTc-sestamibi SPECT\/CT for the diagnosis of renal oncocytomas and hybrid oncocytic\/chromophobe tumors","volume":"69","author":"Gorin","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0160","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.euo.2020.09.005","article-title":"The impact of histological subtype on the incidence, timing, and patterns of recurrence in patients with renal cell carcinoma after surgery\u2014results from RECUR consortium","volume":"4","author":"Abu-Ghanem","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2022.01.040_b0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13550-017-0278-z","article-title":"Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of 99mTc-sestamibi SPECT\/CT","volume":"7","author":"Tzortzakakis","year":"2017","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.eururo.2022.01.040_b0170","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000000932.01","article-title":"Evaluation and risk stratification of renal masses with 99mTc-sestamibi SPECT\/CT","volume":"203","author":"Sistani","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0175","article-title":"The role of Tc-99m MIBI scintigraphy in clinical T1 renal mass assessment: does it have a real benefit?","volume":"38","author":"Asi","year":"2020","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.eururo.2022.01.040_b0180","first-page":"e1224","article-title":"Cost-effectiveness analysis of 99mTc-sestamibi SPECT\/CT to guide management of small renal masses","volume":"203","author":"Su","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2022.01.040_b0185","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(07)70044-X","article-title":"Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial","volume":"8","author":"Divgi","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2022.01.040_b0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2010.03.015","article-title":"Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy","volume":"58","author":"Stillebroer","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0195","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.eururo.2020.09.027","article-title":"The clinicopathologic and molecular landscape of clear cell papillary renal cell carcinoma: implications in diagnosis and management","volume":"79","author":"Weng","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0200","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.7150\/thno.21848","article-title":"Past, present, and future: development of theranostic agents targeting carbonic anhydrase IX","volume":"7","author":"Lau","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.eururo.2022.01.040_b0205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2011.41.2445","article-title":"Positron emission tomography\/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial","volume":"31","author":"Divgi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.01.040_b0210","unstructured":"Wilex AG. Wilex AG and the FDA agree on the further development of REDECTANE(R) 2012. https:\/\/www.dgap.de\/dgap\/News\/corporate\/wilex-and-the-fda-agree-the-further-development-redectaner\/?newsID=734856."},{"key":"10.1016\/j.eururo.2022.01.040_b0215","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00259-013-2679-1","volume":"41","author":"Cheal","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2022.01.040_b0220","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1007\/s00259-021-05271-w","article-title":"Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma","volume":"48","author":"Merkx","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2022.01.040_b0225","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.eururo.2013.02.022","article-title":"Indium-111\u2013labeled Girentuximab ImmunoSPECT as a diagnostic tool in clear cell renal cell carcinoma","volume":"63","author":"Muselaers","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0230","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MNM.0b013e3282f3a515","article-title":"PET versus SPECT: strengths, limitations and challenges","volume":"29","author":"Rahmim","year":"2008","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.eururo.2022.01.040_b0235","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1038\/s41598-019-51445-w","article-title":"Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts","volume":"9","author":"Garousi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2022.01.040_b0240","doi-asserted-by":"crossref","first-page":"56471","DOI":"10.18632\/oncotarget.10602","article-title":"[64Cu]XYIMSR-06: a dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma","volume":"7","author":"Minn","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2022.01.040_b0245","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1102\/1470-7330.2012.0042","article-title":"Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET\/CT in renal cell carcinoma","volume":"12","author":"Wang","year":"2012","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.eururo.2022.01.040_b0250","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MNM.0b013e3283442e3b","article-title":"A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography\/computed tomography in the evaluation of indeterminate renal masses","volume":"32","author":"\u00d6z\u00fclker","year":"2011","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.eururo.2022.01.040_b0255","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/MNM.0000000000000915","article-title":"Role of contrast-enhanced 18F-FDG PET\/CT imaging in the diagnosis and staging of renal tumors","volume":"39","author":"G\u00fcndo\u011fan","year":"2018","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.eururo.2022.01.040_b0260","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/MNM.0000000000001169","article-title":"Semi-quantitative F-18-FDG PET\/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics","volume":"41","author":"Singh","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.eururo.2022.01.040_b0265","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/RLU.0000000000000875","article-title":"Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET\/CT","volume":"40","author":"Takahashi","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2022.01.040_b0270","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00259-020-04996-4","article-title":"2-[18F]FDG PET\/CT parameters associated with WHO\/ISUP grade in clear cell renal cell carcinoma","volume":"48","author":"Zhao","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2022.01.040_b0275","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1007\/s00330-015-4026-3","article-title":"Clinical role of early dynamic FDG-PET\/CT for the evaluation of renal cell carcinoma","volume":"26","author":"Nakajima","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0280","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1007\/s00330-015-3687-2","article-title":"18-F fluorodeoxyglucose uptake in positron emission tomography as a pathological grade predictor for renal clear cell carcinomas","volume":"25","author":"Noda","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0285","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2214\/AJR.19.22467","article-title":"FDG PET\/CT and CT findings of renal cell carcinoma with sarcomatoid differentiation","volume":"215","author":"Zhu","year":"2020","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0290","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eururo.2016.06.019","article-title":"PSMA-targeted 18F-DCFPyL PET\/CT imaging of clear cell renal cell carcinoma: results from a rapid autopsy","volume":"71","author":"Gorin","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0295","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12149-015-1017-z","article-title":"Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET\/CT","volume":"29","author":"Rowe","year":"2015","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.eururo.2022.01.040_b0300","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12149-019-01371-8","article-title":"Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET\/CT","volume":"33","author":"Meyer","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.eururo.2022.01.040_b0305","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00259-020-05165-3","article-title":"(18)F-PSMA-1007 PET\/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results","volume":"48","author":"Mittlmeier","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2022.01.040_b0310","first-page":"1142","article-title":"PSMA-PET\/CT in patients with recurrent clear cell renal cell carcinoma: histopathological correlations of imaging findings","volume":"11","author":"G\u00fchne","year":"2021","journal-title":"Diagnostics (Basel, Switzerland)"},{"key":"10.1016\/j.eururo.2022.01.040_b0315","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2967\/jnumed.120.251272","article-title":"Dynamic 68 Ga-PSMA-11 PET\/CT for the primary evaluation of localized renal mass: a prospective study","volume":"62","author":"Golan","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2022.01.040_b0320","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00259-020-04916-6","article-title":"Comprehensive evaluation of 68Ga-PSMA-11 PET\/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma","volume":"48","author":"Gao","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2022.01.040_b0325","first-page":"33","article-title":"The clinical use of PET with (11)C-acetate","volume":"2","author":"Grassi","year":"2012","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2022.01.040_b0330","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/RLU.0b013e318266cde2","article-title":"Dual-tracer PET\/CT in renal angiomyolipoma and subtypes of renal cell carcinoma","volume":"37","author":"Ho","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2022.01.040_b0335","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2022.01.040_b0340","series-title":"Deep learning","author":"Goodfellow","year":"2016"},{"key":"10.1016\/j.eururo.2022.01.040_b0345","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MOU.0000000000000881","article-title":"Kidney cancer management 3.0: can artificial intelligence make us better?","volume":"31","author":"Lee","year":"2021","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2022.01.040_b0350","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.crad.2019.09.131","article-title":"Usefulness of CT texture analysis in differentiating benign and malignant renal tumours","volume":"75","author":"Deng","year":"2020","journal-title":"Clin Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0355","doi-asserted-by":"crossref","first-page":"W288","DOI":"10.2214\/AJR.18.19551","article-title":"Differentiation of predominantly solid enhancing lipid-poor renal cell masses by use of contrast-enhanced CT: evaluating the role of texture in tumor subtyping","volume":"211","author":"Varghese","year":"2018","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0360","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019725","article-title":"Discriminating malignant and benign clinical T1 renal masses on computed tomography","volume":"99","author":"Uhlig","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.eururo.2022.01.040_b0365","doi-asserted-by":"crossref","first-page":"20200002","DOI":"10.1259\/bjr.20200002","article-title":"Deep learning based classification of solid lipid-poor contrast enhancing renal masses using contrast enhanced CT","volume":"93","author":"Oberai","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0370","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1007\/s00330-020-06787-9","article-title":"Automated classification of solid renal masses on contrast-enhanced computed tomography images using convolutional neural network with decision fusion","volume":"30","author":"Zabihollahy","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0375","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2214\/AJR.19.22074","article-title":"Differentiation of small (\u22644 cm) renal masses on multiphase contrast-enhanced CT by deep learning","volume":"214","author":"Tanaka","year":"2020","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0380","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1158\/1078-0432.CCR-19-0374","article-title":"Deep learning to distinguish benign from malignant renal lesions based on routine MR imaging","volume":"26","author":"Xi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.01.040_b0385","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1007\/s00261-020-02414-9","article-title":"Can whole-tumor radiomics-based CT analysis better differentiate fat-poor angiomyolipoma from clear cell renal cell carcinoma: compared with conventional CT analysis?","volume":"45","author":"Ma","year":"2020","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0390","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1007\/s00330-019-06427-x","article-title":"A CT-based radiomics nomogram for differentiation of renal angiomyolipoma without visible fat from homogeneous clear cell renal cell carcinoma","volume":"30","author":"Nie","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0395","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s00330-019-06384-5","article-title":"Radiomics of small renal masses on multiphasic CT: accuracy of machine learning\u2013based classification models for the differentiation of renal cell carcinoma and angiomyolipoma without visible fat","volume":"30","author":"Yang","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0400","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.crad.2019.02.018","article-title":"The value of quantitative CT texture analysis in differentiation of angiomyolipoma without visible fat from clear cell renal cell carcinoma on four-phase contrast-enhanced CT images","volume":"74","author":"You","year":"2019","journal-title":"Clin Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0405","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/0284185119830282","article-title":"Differentiation of renal angiomyolipoma without visible fat from renal cell carcinoma by machine learning based on whole-tumor computed tomography texture features","volume":"60","author":"Cui","year":"2019","journal-title":"Acta Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0410","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1002\/mp.12258","article-title":"Differentiation of fat-poor angiomyolipoma from clear cell renal cell carcinoma in contrast-enhanced MDCT images using quantitative feature classification","volume":"44","author":"Lee","year":"2017","journal-title":"Med Phys"},{"key":"10.1016\/j.eururo.2022.01.040_b0415","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.acra.2015.04.004","article-title":"Angiomyolipoma with minimal fat","volume":"22","author":"Yan","year":"2015","journal-title":"Acad Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0420","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.acra.2018.06.015","article-title":"Whole-tumor quantitative apparent diffusion coefficient histogram and texture analysis to differentiation of minimal fat angiomyolipoma from clear cell renal cell carcinoma","volume":"26","author":"Li","year":"2019","journal-title":"Acad Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0425","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/mp.12828","article-title":"Deep feature classification of angiomyolipoma without visible fat and renal cell carcinoma in abdominal contrast-enhanced CT images with texture image patches and hand-crafted feature concatenation","volume":"45","author":"Lee","year":"2018","journal-title":"Med Phys"},{"key":"10.1016\/j.eururo.2022.01.040_b0430","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/bju.14985","article-title":"Automated differentiation of benign renal oncocytoma and chromophobe renal cell carcinoma on computed tomography using deep learning","volume":"125","author":"Baghdadi","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2022.01.040_b0435","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1007\/s00330-019-06260-2","article-title":"CT texture analysis in the differentiation of major renal cell carcinoma subtypes and correlation with Fuhrman grade","volume":"29","author":"Deng","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0440","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00261-016-1014-2","article-title":"Subjective and objective heterogeneity scores for differentiating small renal masses using contrast-enhanced CT","volume":"42","author":"Leng","year":"2017","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0445","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.crad.2018.11.009","article-title":"Can quantitative CT texture analysis be used to differentiate subtypes of renal cell carcinoma?","volume":"74","author":"Zhang","year":"2019","journal-title":"Clin Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0450","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1007\/s00261-020-02588-2","article-title":"CT texture analysis for the differentiation of papillary renal cell carcinoma subtypes","volume":"45","author":"Duan","year":"2020","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0455","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2214\/AJR.17.19213","article-title":"Differentiation of papillary renal cell carcinoma subtypes on MRI: qualitative and texture analysis","volume":"211","author":"Vendrami","year":"2018","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0460","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2214\/AJR.14.13279","article-title":"Diagnosis of sarcomatoid renal cell carcinoma with CT: evaluation by qualitative imaging features and texture analysis","volume":"204","author":"Schieda","year":"2015","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0465","doi-asserted-by":"crossref","first-page":"20200131","DOI":"10.1259\/bjr.20200131","article-title":"Prediction models for clear cell renal cell carcinoma ISUP\/WHO grade: comparison between CT radiomics and conventional contrast-enhanced CT","volume":"93","author":"Han","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0470","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s11547-020-01169-z","article-title":"Noninvasive Fuhrman grading of clear cell renal cell carcinoma using computed tomography radiomic features and machine learning","volume":"125","author":"Nazari","year":"2020","journal-title":"Radiol Med"},{"key":"10.1016\/j.eururo.2022.01.040_b0475","article-title":"Prediction of ISUP grading of clear cell renal cell carcinoma using support vector machine model based on CT images","volume":"98","author":"Sun","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.eururo.2022.01.040_b0480","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejrad.2018.10.005","article-title":"Clear cell renal cell carcinoma: CT-based radiomics features for the prediction of Fuhrman grade","volume":"109","author":"Shu","year":"2018","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0485","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1007\/s00330-019-06601-1","article-title":"Predicting the ISUP grade of clear cell renal cell carcinoma with multiparametric MR and multiphase CT radiomics","volume":"30","author":"Cui","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0490","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1177\/0284185120951964","article-title":"The role of MRI texture analysis based on susceptibility-weighted imaging in predicting Fuhrman grade of clear cell renal cell carcinoma","volume":"62","author":"Sun","year":"2021","journal-title":"Acta Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0495","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10278-020-00336-y","article-title":"MRI radiomics for the prediction of Fuhrman grade in clear cell renal cell carcinoma: a machine learning exploratory study","volume":"33","author":"Stanzione","year":"2020","journal-title":"J Digit Imaging"},{"key":"10.1016\/j.eururo.2022.01.040_b0500","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1007\/s00261-020-02495-6","article-title":"Using texture analysis as a predictive factor of subtype, grade and stage of renal cell carcinoma","volume":"45","author":"Ya\u015far","year":"2020","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0505","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/jmri.27153","article-title":"Deep learning based on MRI for differentiation of low- and high-grade in low-stage renal cell carcinoma","volume":"52","author":"Zhao","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.eururo.2022.01.040_b0510","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41571-019-0209-1","article-title":"Towards individualized therapy for metastatic renal cell carcinoma","volume":"16","author":"Kotecha","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eururo.2022.01.040_b0515","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/j.clgc.2021.07.005","article-title":"Molecular subtypes and gene expression signatures as prognostic features in fully resected clear cell renal cell carcinoma: a tailored approach to adjuvant trials","volume":"19","author":"Roussel","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2022.01.040_b0520","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1080\/0284186X.2021.1962971","article-title":"Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications","volume":"60","author":"Roussel","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.eururo.2022.01.040_b0525","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1158\/1078-0432.CCR-21-0706","article-title":"Deciphering intratumoral molecular heterogeneity in clear cell renal cell carcinoma with a radiogenomics platform","volume":"27","author":"Udayakumar","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.01.040_b0530","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1148\/radiol.2015150800","article-title":"The radiogenomic risk score: construction of a prognostic quantitative, noninvasive image-based molecular assay for renal cell carcinoma","volume":"277","author":"Jamshidi","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2022.01.040_b0535","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.crad.2018.04.009","article-title":"Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma","volume":"73","author":"Yin","year":"2018","journal-title":"Clin Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0540","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1007\/s00261-015-0386-z","article-title":"Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA\u2013RCC) Imaging Research Group","volume":"40","author":"Shinagare","year":"2015","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.eururo.2022.01.040_b0545","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Creighton","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2022.01.040_b0550","doi-asserted-by":"crossref","first-page":"W55","DOI":"10.2214\/AJR.18.20443","article-title":"Radiogenomics in clear cell renal cell carcinoma: machine learning\u2013based high-dimensional quantitative CT texture analysis in predicting PBRM1 mutation status","volume":"212","author":"Kocak","year":"2019","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0555","doi-asserted-by":"crossref","first-page":"41009","DOI":"10.1117\/1.JMI.2.4.041009","article-title":"Imaging-genomic pipeline for identifying gene mutations using three-dimensional intra-tumor heterogeneity features","volume":"2","author":"Ghosh","year":"2015","journal-title":"J Med Imaging (Bellingham, Wash)"},{"key":"10.1016\/j.eururo.2022.01.040_b0560","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1007\/s00330-018-5872-6","article-title":"Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective","volume":"29","author":"Li","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0565","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/aae5cd","article-title":"Reliable gene mutation prediction in clear cell renal cell carcinoma through multi-classifier multi-objective radiogenomics model","volume":"63","author":"Chen","year":"2018","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.eururo.2022.01.040_b0570","doi-asserted-by":"crossref","unstructured":"Marigliano C, Badia S, Bellini D, et al. Radiogenomics in clear cell renal cell carcinoma: correlations between advanced CT imaging (texture analysis) and MicroRNAs expression. Technol Cancer Res Treat 2019;18:153303381987845.","DOI":"10.1177\/1533033819878458"},{"key":"10.1016\/j.eururo.2022.01.040_b0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238809","article-title":"MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets","volume":"15","author":"Verbiest","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2022.01.040_b0580","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3390\/cancers13071554","article-title":"MicroRNAs possibly involved in the development of bone metastasis in clear-cell renal cell carcinoma","volume":"13","author":"Kinget","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2022.01.040_b0585","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2214\/AJR.19.21709","article-title":"Radiomics of renal masses: systematic review of reproducibility and validation strategies","volume":"214","author":"Kocak","year":"2020","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0590","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2214\/AJR.20.22847","article-title":"Artificial intelligence in renal mass characterization: a systematic review of methodologic items related to modeling, performance evaluation, clinical utility, and transparency","volume":"215","author":"Kocak","year":"2020","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2022.01.040_b0595","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1007\/s00330-020-06666-3","article-title":"Radiomics of computed tomography and magnetic resonance imaging in renal cell carcinoma\u2014a systematic review and meta-analysis","volume":"30","author":"Ursprung","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2022.01.040_b0600","doi-asserted-by":"crossref","unstructured":"Pedrosa I, Cadeddu JA. How we do it: managing the indeterminate renal mass with the MRI clear cell likelihood score. Radiology. In press. https:\/\/doi.org\/10.1148\/radiol.210034.","DOI":"10.1148\/radiol.210034"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822000835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822000835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:11:39Z","timestamp":1759583499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283822000835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":120,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0302283822000835"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.01.040","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.01.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}